Skip to main content

Table 4 Summary characteristics, use of medication at baseline and outcome-response during 2-year follow-up in adolescents with (JIA) (n = 15) receiving (IACs) to the (TMJs) (n = 22)

From: Efficacy and safety of intraarticular corticosteroid injections in adolescents with juvenile idiopathic arthritis in the temporomandibular joint: a Norwegian 2-year prospective multicenter pilot study

Case M/F Age Onset Age
Inj
Dose inj (mg) Medic (T0) Medic (T1) Medic (T2) Medic (T3) MIO Pain index MRI additive inflammatory domaina MRI Progressive inflammationa MRI additive damage domaina MRI progressive osseous deformitya Comments
1 M 10 10 6 MTX MTX MTX   T0: 48
T1: 42
T2: 48
T3: -
T0: 6
T1
T2: 2
T3: -
T0: 6
T1: 4
T2: 6
T3: -
T0: 3
T1: 3
T2: 4
T3: -
T0: 3
T1: 4
T2: 4
T3: -
T0: 3
T1: 3
T2: 4
T3: -
Bilateral IACs
Mandibular trauma between T1 and T2
2 F 17 17 8 MTX BioCo BioCo BioCo T0: 40
T1: -
T2: 37
T3: -
T0: 0
T1: -
T2: -
T3: -
T0: 3
T1: 2
T2: 5
T3: 1
T0: 3
T1: 2
T2: 3
T3: 1
T0: 4
T1: 4
T2: 3
T3: 3
T0: 3
T1: 3
T2: 3
T3: 3
Unilateral IACs
3 F 11 11 8 MTX MTX BioCo   T0: 32
T1: 35
T2: 30
T3: -
T0: 9
T1: 0
T2: 0
T3: -
T0: 5
T1: 5
T2: 5
T3: -
T0: 3
T1: 3
T2: 3
T3: -
T0: 3
T1: 3
T2: 2
T3: -
T0: 3
T1: 2
T2: 0
T3: -
Unilateral IACs
4 F 13 14 20 No DMARD No DMARD No DMARD No DMARD T0: 44
T1: 48
T2: 41
T3: 47
T0: 0
T1: 0
T2: 9
T3: 0
T0: 4
T1: 2
T2: -
T3: -
T4: -
T0: 4
T1: 1
T2: -
T3: 1
T4: 2
T0: 2
T1: 4
T2: 5
T3: 4
T4: 4
T0: 2
T1: 2
T2: 3
T3: 3
T4: 3
Unilateral repeated IACs
(13 months interval)
5 F 9 15 20 BioCo   BioCo   T0: 48
T1: -
T2: -
T3: -
T0: 3
T1: -
T2: -
T3: 0
T0: 6
T1: -
T2: 6
T3: -
T0: 3
T1: -
T2: 3
T3: -
T0: 1
T1: -
T2: 4
T3: -
T0: 0
T1: -
T2: 2
T3: -
Unilateral IACs
6 F 9 14 10 BioCo BioCo BioCo BioCo T0: 46
T1: 45
T2: 47
T3: 47
T0: 5.5
T1: 2
T2: 0
T3: 0
T0: 1
T1: 1
T2: 1
T3: 1
T0: 1
T1: 1
T2: 1
T3: 1
T0: 0
T1: 0
T2: 0
T3: 0
T0: 0
T1: 0
T2: 0
T3: 0
Bilateral IACs
7 F 2 15 20 No DMARD No DMARD No DMARD MTX T0: 36
T1: 44
T2: 44
T3: 44
T0: 36
T1: 10
T2: 6
T3: 0
T0: 3
T1: 3
T2: 3
T3: 1
T0: 1
T1: 1
T2: 2
T3: 1
T0: 1
T1: 2
T2: 1
T3: 1
T0: 0
T1: 1
T2: 0
T3: 0
Bilateral IACs
8 F 15 16 40b No DMARD No DMARD MTX   T0: 45
T1: 46
T2: 50
T3: -
T0: 0
T1: 0
T2: 12
T3: -
T0: 2
T1: 2
T2: 2
T3: -
T0: 2
T1: 2
T2: 2
T3: -
T0: 4
T1: 4
T2: 4
T3: -
T0: 2
T1: 2
T2: 2
T3: -
Unilateral IACs
9 F 0 15 20 BioCo BioCo BioCo No DMARD T0: 49
T1: 54
T2: 54
T3: 45
T0: 0
T1: 5
T2: 0
T3: -
T0: 2
T1: 0
T2: 2
T3: 2
T0: 2
T1: 0
T2: 2
T3: 2
T0: 4
T1: 2
T2: 2
T3: 2
T0: 2
T1: 2
T2: 2
T3: 2
Unilateral IACs
10 F 15 16 20 No DMARD No DMARD MTX MTX T0: 45
T1: 44
T2: 49
T3: 48
T0: 12
T1: 22.5
T2: 0
T3: 6
T0: 5
T1: 6
T2: 4
T3: 2
T4: 3
T0: 3
T1: 3
T2: 3
T3: 1
T4: 3
T0: 3
T1: 3
T2: 3
T3: 4
T4: 3
T0: 3
T1: 3
T2: 3
T3: 3
T4: 3
Unilateral repeated IACs
(11 months interval)
11 M 11 16 20 No DMARD No DMARD No DMARD No DMARD T0: 55
T1: 55
T2: 62
T3: 63
T0: 0
T1: 0
T2: 0
T3: 0
T0: 5
T1: 4
T2: 2
T3: 5
T0: 2
T1: 1
T2: 1
T3: 2
T0: 3
T1: 3
T2: 3
T3: 3
T0: 3
T1: 2
T2: 2
T3: 2
Unilateral injection
12 M 8 9 10 BioCo BioCo BioCo BioCo T0: 34
T1: 40
T2: 41
T3: 45
T0: 7.5
T1: 0
T2: 0
T3: 0
T0: 7
T1: 3
T2: 1
T3: 0
T0: 3
T1: 3
T2: 1
T3: 0
T0: 0
T1: 0
T2: 0
T3: 0
T0: 0
T1: 0
T2: 0
T3: 0
Bilateral IACs
13 F 14 15 16 BioCo BioCo BioCo BioCo T0: 42
T1: 44
T2: 45
T3: 46
T0: 21
T1: 14
T2: 2.5
T3: 5
T0: 6
T1: 6
T2: 5
T3: 5
T0: 3
T1: 3
T2: 3
T3: 3
T0: 5
T1: 5
T2: 5
T3: 5
T0: 3
T1: 3
T2: 3
T3: 3
Unilateral IACs
14 F 5 11 20 BioCo BioCo BioCo BioCo T0: 43
T1: 45
T2: 44
T3: 48
T0: 13
T1: 9
T2: 9
T3: 12
T0: 5
T1: -
T2: 4
T3: 3
T0: 3
T1: -
T2: 3
T3: 3
T0: 3
T1: 2
T2: 2
T3: -
T0: 3
T1: 3
T2: 3
T3: 3
Unilateral IACs
15 F 13 15 20 No DMARD - No DMARD MTX T0: 35
T1: 45
T2: 45
T3: 45
T0: 32
T1: -
T2: 8
T3: 3
T0: 6
T1: 6
T2: 4
T3: 3
T0: 3
T1: 3
T2: 4
T3: 2
T0: 3
T1: 3
T2: 3
T3: 3
T0: 3
T1: 3
T2: 3
T3: 3
Bilateral IACs
  1. aAdditive and progressive MRI score [40, 41]
  2. bMetylprednisolone acetate
  3. Inj injection, Medic medication, MIO maximal incisal opening, MRI magnetic resonance imaging, FU follow-up, MTX methotrexate, BioCo biologics alone or in combination with other, DMARDs disease modifying antirheumatic drugs, JIA juvenile idiopathic arthritis, TMJ temporomandibular joint, IACs intraarticular corticosteroid injections; T0 = Pre-injection, T1 = 2-months follow-up, T2 = 1-year follow-up, T3 = 2-year follow-up; − missing data " - "